Voxmind | $735,203 | (Jun 2, 2026)
Invertix | $1,977,831 | (Jun 2, 2026)
XCENA | $135,000,000 | (Jun 2, 2026)
Certified by Founder
Lodge
Clarametyx Biosciences
start up
United States
- Columbus, Ohio
- 08/01/2024
- Series A
- $33,000,000
Clarametyx Biosciences Inc. is a clinical stage biotechnology company developing immune-enabling biologic therapies to fight life-threatening infections. Our novel technology platform targets the protective barrier around bacteria, known as biofilms.
- Industry Biotechnology Research
- Website https://clarametyx.com/
- LinkedIn https://www.linkedin.com/company/clarametyx-biosciences/about/
Related People
David V. RichardsFounder
United States -
Columbus, Ohio
Life sciences executive and entrepreneur with a passion for building transformative science into compelling companies. Focus on high patient need categories that hold the potential for broad impact on national and global health, with a personal interest in infectious disease, neurocognitive and genetic disorders.
Inherent | $50,000,000 | (Jun 2, 2026)
Gray Swan | $40,000,000 | (Jun 2, 2026)
Handshake(UK) | $3,200,000 | (Jun 2, 2026)
Sekai(US) | $26,000,000 | (Jun 2, 2026)
Human Archive (YC W26) | $8,200,000 | (Jun 2, 2026)
Perceptic | $12,000,000 | (Jun 2, 2026)
SpeedLabs | $6,500,000 | (Jun 2, 2026)
MokN | $15,000,000 | (May 29, 2026)
Orebella | Undisclosed Amount | (May 29, 2026)